Intellia Therapeutics, Inc. (NTLA): Capital Expenditures
$1.13M
Year ended 2025-12-31
$2.04M
Trailing 12 months to 2026-06-30
-56.3%
3-year compound annual growth
-20.6%
5-year compound annual growth
-7.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.13M | -80.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $5.78M | -58.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $13.98M | +3.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $13.56M | +6.3% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $12.76M | +255.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $3.58M | -47.2% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $6.79M | +6.9% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $6.36M | -37.0% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $10.09M | +63.7% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $6.17M | +141.4% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $2.55M | n/a | 2018-03-14, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $1.13M | -80.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $1.15M | +2.0% |
| Immucell Corp (ICCC) | 2025-12-31 | $1.25M | +168.5% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $16.0K | -56.8% |
| Neogen Corp (NEOG) | 2026-05-31 | $51.30M | -51.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $3.19M | +517.2% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $89.6K | -67.7% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $188.20M | -3.5% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $2.71M | +41.4% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗